Anuh Pharma Q1 FY27 Results & Earnings Intelligence
ANUHPHRStructural risk assessment following Q1-FY27 | 30 Jun 26 earnings.
₹196.9 Cr
+3.7% YoY•-2.0% QoQ
₹16.9 Cr
+54.6% YoY•+9.1% QoQ
₹11.4 Cr
+37.6% YoY•-2.2% QoQ
19/ 100
+5 pts QoQ
The Quarter at a Glance
Consolidated Financials| Metric | Q1-FY27 | 30 Jun 26 | Q1-FY26 | 30 Jun 25 | YoY Δ | Q4-FY26 | 31 Mar 26 | QoQ Δ |
|---|---|---|---|---|---|
| Total Revenue / Income | ₹196.9 Cr | ₹189.9 Cr | +3.7% | ₹200.9 Cr | -2.0% |
| Profit Before Tax (PBT) | ₹16.9 Cr | ₹11.0 Cr | +54.6% | ₹15.5 Cr | +9.1% |
| Net Profit (PAT) | ₹11.4 Cr | ₹8.3 Cr | +37.6% | ₹11.7 Cr | -2.2% |
| Basic EPS (₹/share) | ₹1.14 | N/A | N/A | N/A | N/A |
Sources:Official BSE/NSE Disclosures & Financial Filings
Sentinel Executive Summary
Core Earnings Synthesis"Anuh Pharma Limited currently sits within Flagium's Stable category. However, recent periods have introduced early signs of competitive and operating pressure. Despite positive top and bottom-line growth, triggers like 'Universal Inventory Divergence', 'Industrial Margin Stress' indicate underlying structural risk. Current deterioration appears cyclical rather than existential."
Anuh Pharma Limited posted steady top-line growth and bottom-line stability, demonstrating resilient execution in its core markets. While the underlying business remains fundamentally sound, the presence of 2 active risk warnings highlights minor operational or working capital inefficiencies to keep on the watch list.
🟢 Key Operational & Structural Positives
- ✓Revenue Growth: Quarterly revenue moved +3.7% YoY and -2.0% QoQ, reflecting demand and volume trends.
- ✓Net Profit Expansion: Profit after tax moved +37.6% YoY and -2.2% QoQ, settling at ₹11.4 Cr.
- ✓Operating Margins: Operating margin moved +283 bps YoY and +87 bps QoQ to 8.60%.
⚠️ Key Areas of Watch & Margin Pressures
- ⚠Resolution of 'Universal Inventory Divergence': ANUHPHR: Inventory growth outpaced Revenue growth by +17.5 pp (Inventory holding ratio increased +16.3%).
- ⚠Resolution of 'Industrial Margin Stress': ANUHPHR: Raw material costs consumed an additional 16.0% of revenue YoY.
- ⚠Raw material inflation: Input costs consumed 81.2% of revenue (up +1599 bps YoY), watch gross margin defense.
Total Revenue / Income grew +3.7% YoY, but moderated -2.0% QoQ vs Q4-FY26. This divergence typically reflects seasonal lumpiness or elevated base in prior quarters rather than secular deterioration; underlying annual growth remains intact. Similarly, Net Profit (PAT) moderated -2.2% QoQ while maintaining +37.6% YoY.
Flagium Risk Signals
Automated Forensic SignalsUniversal Inventory Divergence • Industrial Margin Stress
ANUHPHR: Inventory growth outpaced Revenue growth by +17.5 pp (Inventory holding ratio increased +16.3%).
ANUHPHR: Raw material costs consumed an additional 16.0% of revenue YoY.
Capital Allocation & Shareholder Return
DividendBoard approved capital distribution for Q1-FY27
₹1.50 / share
Approved by Board05-Aug-2026
Shareholder Cut-off131.6%
Exceeds Quarterly EPSWithin 30 Days
Statutory Window🎙️ Anuh Pharma (ANUHPHR) Q1 FY27 Concall Intelligence
Management Commentary, Concall Takeaways & Key Discussion Themes
No earnings call transcript was available
for this reporting period.
What to do next
Explore ANUHPHR's full structural risk profile — 12Q score trajectory, pillar breakdown, flag history, and peer benchmarking.
View ANUHPHR profile →See how Healthcare peers and the broader market are positioned. Identify sector-wide stress or rotation signals.
Open market monitor →Check how this Q1-FY27 | 30 Jun 26 result affects your portfolio's overall risk exposure and concentration.
Review your portfolio →Continue Research
📬 Flagium Risk Brief — Track forensic risks on ANUHPHR & 3 market anomalies weekly
See a sample issue →Methodology & Regulatory Disclaimer
Flagium AI is an automated financial data analytics platform. Analysis reports are compiled programmatically from public regulatory XBRL submissions (NSE/BSE) for educational and research purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. This evaluation does not constitute investment advice, financial planning, or recommendations to buy, sell, or hold any security.
Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.